Up-regulation of Vascular Endothelial Growth Factor-C by Nicotine in Cervical Cancer Cell Lines
Article first published online: 23 FEB 2005
American Journal of Reproductive Immunology
Volume 53, Issue 3, pages 153–158, March 2005
How to Cite
Lane, D., Gray, E. A., Mathur, R. S. and Mathur, S. P. (2005), Up-regulation of Vascular Endothelial Growth Factor-C by Nicotine in Cervical Cancer Cell Lines. American Journal of Reproductive Immunology, 53: 153–158. doi: 10.1111/j.1600-0897.2005.00259.x
- Issue published online: 23 FEB 2005
- Article first published online: 23 FEB 2005
- Submitted October 20, 2004; revised December 29, 2004; accepted January 10, 2005.
- cervical cancer;
- epidermal growth factor receptor;
- human papilloma virus E6;
- transforming growth factor-β;
- vascular endothelial growth factor-C
Problem: Smoking and infection with human papilloma virus (HPV) are major risk factors for cervical cancer. Our earlier work shows that nicotine enhances cellular proliferation of cervical cancer cell lines by up-regulating epidermal growth factor (EGF) and its receptor EGF-R, which leads to increased insulin-like growth factor II in vitro. We found that the vascular endothelial growth factor (VEGF)-C, one of the five isoforms of VEGF, may be specifically involved in lymphogenic metastasis of cervical cancer. This has prompted us to study if in vitro nicotine treatment will up-regulate VEGF-C alongside EGF-R levels, while down regulating the anti-proliferative transforming growth factor (TGF)-β levels in HPV positive cervical cancer cell lines.
Method of study: Cervical cancer cell lines CaSki, HeLa and ME-180, were cultured in serum free DMEM medium for 24-hr, and treated with 10 ng/mL nicotine in the medium supplemented with 10% fetal bovine serum. A group of untreated cells served as controls. The cells were cultured in chamber slides (for immunofluorescent antibody assay) as well as microtiter plate wells (for BrdU cell proliferation assay). The cellular levels of VEGF-C, TGF-β, EGF-R and HPV-E6 (early protein 6) were measured by a semi-quantitative immunofluorescent antibody assay. The cell proliferation and immunofluorescent assay data were analyzed by a Student's t-test.
Results: Cell proliferation was significantly increased after nicotine treatment in all the cell lines. The VEGF-C levels were significantly increased, while TGF-β levels were decreased by nicotine in all the cell lines (P < 0.00001). EGF-R levels were also significantly increased after nicotine treatment in HeLa and ME-180, while HPV-E6 levels remained unchanged in all three.
Conclusions: Nicotine up regulates expression of cell proliferative VEGF-C and EGF-R, while down-regulating anti-proliferative TGF-β. Our data suggest that nicotine in circulation and in cervical squamous epithelial cells may promote not only rapid tumor growth but its lympho-angiogenic spread (VEGF-C) as well. It appears that nicotine does not promote HPV spread in the cervical cancer cells.